Lack of pharmacokinetic interaction between oxcarbazepine and lamotrigine

Neuropsychopharmacology

Volumn 30, Issue 12, 2005, Pages 2269-2274

  Theis, Jochen G W ^a   Sidhu, Jagdev ^b   Palmer, Joanne ^b   Job, Sarah ^b   Bullman, Jonathan ^b   Ascher, John ^c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Bipolar disorder; Cotherapy; Epilepsy; Lamotrigine; Oxcarbazepine; Pharmacokinetics

Indexed keywords

DRUG METABOLITE; LAMOTRIGINE; OXCARBAZEPINE; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG BLOOD LEVEL; DRUG TOLERABILITY; ELECTROCARDIOGRAM; HEADACHE; HUMAN; MALE; NAUSEA; NORMAL HUMAN; PHARMACOLOGICAL PARAMETERS; PHARYNGITIS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SOMNOLENCE; STEADY STATE;

ADOLESCENT; ADULT; ANTICONVULSANTS; AREA UNDER CURVE; CARBAMAZEPINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; HUMANS; MALE; MIDDLE AGED; SPECTROPHOTOMETRY, ULTRAVIOLET; TRIAZINES;

EID: 27844609389     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300831     Document Type: Article

References (26)

1. Anderson GD, Gidal BE, Messenheimer JA, Gilliam FG (2002). Time course of lamotrigine de-induction: impact of step-wise withdrawal of carbamazepine or phenytoin. Epilepsy Res 49: 211-217.
2. Callaham ML, Wears RL, Weber EJ, Barton C, Young G (1998). Positive-outcome bias and other limitations in the outcome of research abstracts submitted to a scientific meeting. JAMA 280: 254-257 [Erratum in: JAMA (1998) 280: 1232.].
3. Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW (1987). Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther 42: 535-541.
4. Deckers CL, Hekster YA, Keyser A, Meinardi H, Renier WO (1997). Drug load in clinical trials: a neglected factor. Clin Pharmacol Ther 62: 592-595.
5. Deckers CLP (2002). The place of combination therapy in the early treatment of epilepsy. CNS Drugs 16: 155-163.
6. Fattore C, Cipolla G, Gatti G, Limido GL, Sturm Y, Bernasconi C et al (1999). Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia 40: 783-787.
7. Flesch G (2004). Overview of the clinical pharmacokinetics of oxcarbazepine. Clin Drug Invest 24: 185-203.
8. Food and Drug Administration (2003). Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations, http://www.fda.gov/cder/guidance/index.htm.
9. Glauser TA (2001). Oxcarbazepine in the treatment of epilepsy. Pharmacotherapy 21: 904-919.
10. Goa KL, Ross SR, Chrisp P (1993). Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 46: 152-176.
11. Greenblatt DJ, von Moltke LL, Harmatz JS, Chen G, Weemhoff JL, Jen C. et al (2003). Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. Clin Pharmacol Ther 74: 121-129.
12. Guenault N, Odou P, Robert H (2003). Increase in dihydroxycarbamazepine serum levels in patients co-medicated with oxcarbazepine and lamotrigine. Eur J Clin Pharmacol 59: 781-782.
13. Hirschfeld RM, Kasper S (2004). A review of the evidence for carbamazepine and oxcarbazepine in the treatment of bipolar disorder. Int J Neuropsychopharmacol 30: 1-16 [Epub ahead of print].
14. Hulsman JARJ, Rentmeester TW, Banfield CR, Reidenberg P, Colucci RD, Meehan JW et al (1995). Effects of felbamate on the pharmacokinetics of the monohydroxy and dihydroxy metabolites of oxcarbazepine. Clin Pharmacol Ther 58: 383-389.
15. Keranen T, Jolkkonen J, Jensen PK, Menge GP, Andersson P (1992a). Absence of interaction between oxcarbazepine and erythromycin. Acta Neurol Scand 86: 120-123.
16. Keranen T, Jolkkonen J, Klosterskov-Jensen P, Menge GP (1992b). Oxcarbazepine does not interact with cimetidine in healthy volunteers. Acta Neurol Scand 85: 239-242.
17. Kramer G, Dorn T, Etter H (2003). Oxcarbazepine: clinically relevant drug interaction with lamotrigine. Epilepsia 44(Suppl 9): 95-96; Abstract No. 1.267. Presented at the Annual Meeting of the American Epilepsy Society. Boston, MA, USA, 05 December 2003-10 December 2003.
18. Lamictal® (lamotrigine) [package insert] (2004) GlaxoSmithKline: Research Triangle Park, NC.
19. Lloyd P, Flesch G, Dieterle W (1994). Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia 35(Suppl 3): S10-S13.
20. May TW, Korn-Merker E, Rambeck B (2003). Clinical pharmacokinetics of oxcarbazepine. Clin Pharmacokinet 42: 1023-1042.
21. May TW, Rambeck B, Jurgens U (1999). Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study. Ther Drug Monit 21: 175-181.
22. Ohnhaus EE, Breckenridge AM, Park BK (1989). Urinary excretion of 6 beta-hydroxycortisol and the time course measurement of enzyme induction in man. Eur J Clin Pharmacol 36: 39-46.
23. Park BK, Breckenridge AM (1981). Clinical implications of enzyme induction and enzyme inhibition. Clin Pharmacokinet 6: 1-24.
24. Shorvon S (2000). Oxcarbazepine: a review. Seizure 9: 75-79.
25. Tecoma ES (1999). Oxcarbazepine. Epilepsia 40(Suppl 5): S37-S46.
26. Trileptal® (oxcarbazepine) [package insert] (2004) Novartis: East Hanover, NJ.